Royalty Pharma (RPRX) Accounts Payables (2019 - 2026)

Royalty Pharma has disclosed Accounts Payables across 8 years of filings, most recently posting $25.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $25.5 million, down 32.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.5 million (down 32.28% YoY), and the FY2025 annual result was $19.4 million, up 45.13% from the prior year.
• Accounts Payables came in at $25.5 million for Q1 2026 at Royalty Pharma, up from $19.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $41.4 million in Q3 2025 to a low of $5.8 million in Q2 2023.
• The 5-year median for Accounts Payables is $15.2 million (2023), against an average of $17.6 million.
• Across the five-year window, Accounts Payables plunged 52.29% in 2023 and soared 303.1% in 2024, its largest moves.
• Royalty Pharma's Accounts Payables stood at $7.9 million in 2022, then jumped by 91.82% to $15.2 million in 2023, then slipped by 11.84% to $13.4 million in 2024, then soared by 45.13% to $19.4 million in 2025, then soared by 31.33% to $25.5 million in 2026.
• The last three Accounts Payables figures came in at $25.5 million (Q1 2026), $19.4 million (Q4 2025), and $41.4 million (Q3 2025), per Business Quant data.